Johnson & Johnson Stock Price, News & Analysis

Johnson & Johnson (NYSE: JNJ) will participate in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 16, 2022, at the Terranea Resort in Rancho Palos Verdes, CA. Jennifer Taubert, Executive VP and Worldwide Chairman of Pharmaceuticals, will represent the company during a session at 1:00 p.m. (Eastern Time). Interested investors can access the live webcast on the Johnson & Johnson website, and a replay will be available approximately 48 hours after the event.

Johnson & Johnson (NYSE: JNJ) has appointed Thibaut Mongon as CEO Designate and Paul Ruh as CFO Designate for its upcoming New Consumer Health Company, set to separate in 2023. This transition aims to enhance focus and growth for both the new entities, following a strategy announced in November 2021 to address industry-specific needs. Mongon, with over 20 years at JNJ, has led significant consumer health innovations, while Ruh brings extensive financial experience from his tenure in the consumer goods sector. The separation is anticipated to unlock value and improve operational agility.

Johnson & Johnson (NYSE: JNJ) will participate in the Bernstein 38th Annual Strategic Decisions Conference on June 1, 2022, at the New York Hilton Midtown. The CEO, Joaquin Duato, will represent the company during a session at 10:00 a.m. (Eastern Time). Investors can access the live webcast via the Johnson & Johnson website at www.investor.jnj.com. A replay of the webcast will be available approximately 48 hours after the live event.

Johnson & Johnson (NYSE: JNJ) has launched a new Satellite Center for Global Health Discovery in Cape Town, South Africa, as part of its ongoing commitment to combat antimicrobial resistance (AMR). This center, developed in collaboration with the Holistic Drug Discovery and Development (H3D) Centre, aims to address the urgent health challenge posed by multidrug-resistant Gram-negative bacteria. The initiative seeks to enhance Africa's scientific capacity and stimulate local innovation by leveraging the strengths of both organizations.

Johnson & Johnson (NYSE: JNJ) will attend the UBS Global Healthcare Conference on May 24, 2022. Mathai Mammen, Executive Vice President of Pharmaceuticals R&D, will represent the company during a session at 10:00 a.m. ET. Interested investors can access the live webcast and subsequent replay, which will be available approximately 48 hours later, through the Johnson & Johnson website.

Johnson & Johnson (NYSE: JNJ) reported Q1 2022 sales of $23.4 billion, a 5.0% increase, with operational growth at 7.7%. Adjusted earnings per share rose 3.1% to $2.67, while diluted EPS fell 16.8% to $1.93. The suspension of COVID-19 Vaccine sales guidance reflects a global supply surplus and demand uncertainty, though it won't affect adjusted operational EPS guidance. The Pharmaceutical segment drove growth, particularly from DARZALEX and STELARA. Consumer Health sales declined slightly, impacted by supply constraints, while MedTech saw an 8.6% increase in adjusted operational sales.

Johnson & Johnson (NYSE: JNJ) has declared a 6.6% increase in its quarterly dividend, raising it from $1.06 to $1.13 per share. This marks the 60th consecutive year of dividend increases, reflecting the company's strong financial position and future confidence. The annual dividend now stands at $4.52 per share, up from $4.24. Shareholders can expect the next dividend payment on June 7, 2022, with the record date on May 24, 2022 and ex-dividend date on May 23, 2022.

Johnson & Johnson (NYSE: JNJ) will participate in the BofA Securities 2022 Healthcare Conference on May 11 at the Encore Hotel in Las Vegas, Nevada. Ashley McEvoy, Executive Vice President and Worldwide Chairman of MedTech, will represent the company during a session at 3:40 p.m. ET. Investors can access the conference call and additional information via the Johnson & Johnson website. A replay of the webcast and podcast will be available approximately 48 hours after the live event.